A new venture capital fund aimed at funding cash-starved Australian medical, biotech and health technology start-ups has banked $40 million of a planned $200 million, as public valuations hit record lows.

Hashan De Silva, a biotech investor who cut his teeth as the first hire at private and public equity outfit Karst Peak, is hoping to take on cashed-up pharmaceutical giants as the first consolidation shoots begin to show.